CBPO [China Biologic Products] 6-K: China Biologic Reports Financial Results for the Fourth

Ticker: CBPO, Company: China Biologic Products Holdings, Inc., Type: 6-K, Date: 2020-03-12
Original SEC Filing: Click here


Webplus: CBPO/20200312/6-K_1/2_EX-99.1/000.htm SEC Original: tm2012199d1_ex99-1.htm
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019 BEIJING, China – March 12, 2020 – Fourth Quarter 2019 Financial Highlights · Total sales · Gross profit Gross margin · Income from operations Operating margin · Non-GAAP adjusted income from operations · Net income attributable to the Company Diluted earnings per share · Non-GAAP adjusted net




Webplus: CBPO/20200312/6-K_1/3_EX-99.2/000.htm SEC Original: tm2012199d1_ex99-2.htm
China Biologic Fourth Quarter and Fiscal Year 2019 Financial Results Fourth Quarter 2019 Financial Performance Total sales Total sales for plasma products increased by 2.7% in RMB terms, or 1.0% in USD terms, to $91.2 million from $90.3 million in the same quarter of 2018, as a result of increased sales of special immunoglobulin and coagulation factor products, which was




Webplus: CBPO/20200312/6-K_1/1/000.htm SEC Original: tm2012199-1_6k.htm



Company Info:

Ticker: CBPO, Company: China Biologic Products Holdings, Inc., Type: 6-K, Date: 2020-03-12CIK: 0001369868, Location: F4, SIC: 2836, SIC Desc: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Business Phone & Address:
18TH FL, JIALONG INTERNATIONALBUILDING, 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT
BEIJING 100125

Home Page Forums

By | 2020-10-01T02:01:15+00:00 March 12th, 2020|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar